SCHEMBL17486855

SCHEMBL17486855

C=Cc1ccccc1S(=O)(=O)NCCNc1cccc2ccccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCHE P06276 3/20 0.51
▸ ALDH1A1 P00352 3/20 0.48
▸ HSD17B10 Q99714 3/20 0.48
▸ SCN1A P35498 2/20 0.48
▸ SCN2A Q99250 2/20 0.48
▸ SCN3A Q9NY46 2/20 0.48
▸ KDM4E B2RXH2 2/20 0.48
▸ CYP1A2 P05177 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ CYP2C19 P33261 1/20 0.48
▸ NPY5R Q15761 6/20 0.46
▸ CA12 O43570 2/20 0.45
▸ CA4 P22748 2/20 0.45
▸ CA7 P43166 2/20 0.45
▸ CA9 Q16790 2/20 0.45
▸ CA14 Q9ULX7 2/20 0.45
▸ CA3 P07451 1/20 0.44
▸ CA6 P23280 1/20 0.44
▸ CA5A P35218 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19287497 0.81 BCHE (0.54) BCHEALDH1A1HSD17B10SCN1ASCN2A
SCHEMBL17486853 0.80 BCHE (0.51) BCHEALDH1A1HSD17B10SCN1ASCN2A
SCHEMBL17486848 0.79 BCHE (0.58) BCHEALDH1A1HSD17B10SCN1ASCN2A
SCHEMBL17486854 0.78 HTR1B (0.49) BCHEALDH1A1HSD17B10SCN1ASCN2A
SCHEMBL17489495 0.78 ALDH1A1 (0.42) ALDH1A1HSD17B10SCN1ASCN2ASCN3A
SCHEMBL27393985 0.73 RECQL (0.42) ALDH1A1HSD17B10SCN1ASCN2ASCN3A
SCHEMBL11283741 0.72 CA12 (0.77) BCHEALDH1A1HSD17B10KDM4ECYP1A2
Hydrochloric Acid SCHEMBL4443499 0.71 ALDH1A1 (0.78) BCHEALDH1A1HSD17B10KDM4ECYP3A4
SCHEMBL28403260 0.70 HTR6 (0.50) CA9KEAP1HTR6
SCHEMBL16687465 0.70 CA12 (0.67) BCHEALDH1A1HSD17B10KDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9745319-B2 Irreversible covalent inhibitors of the GTPase K-Ras G12C ARAXES PHARMA LLC (US) 2017-08-29 — — US disclosed
US-9745319-B2 Irreversible covalent inhibitors of the GTPase K-Ras G12C ARAXES PHARMA LLC (US) 2017-08-29 — — US disclosed
US-20160031898-A1 IRREVERSIBLE COVALENT INHIBITORS OF THE GTPASE K-RAS G12C ARAXES PHARMA LLC 2016-02-04 — — US disclosed
US-20160031898-A1 IRREVERSIBLE COVALENT INHIBITORS OF THE GTPASE K-RAS G12C ARAXES PHARMA LLC 2016-02-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160031898-A1 IRREVERSIBLE COVALENT INHIBITORS OF THE GTPASE K-RAS G12C KRAS, HRAS, NRAS BCHE 3457/4885ALDH1A1 3265/4885HSD17B10 4126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback